The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio
Open accessAbstract
The amyloid peptides Aβ(40) and Aβ(42) of Alzheimer's disease are thought to contribute differentially to the disease process. Although Aβ(42) seems more pathogenic than Aβ(40), the reason for this is not well understood. We show here that small alterations in the Aβ(42):Aβ(40) ratio dramatically affect the biophysical and biological properties of the Aβ mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo. A minor increase in the Aβ(42):Aβ(40) ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these Aβ species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non-toxic intermediates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ40 is present in larger amounts in the brain, yet Aβ42 is more neurotoxic and has a higher tendency to aggregate.8–11”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the longer and more hydrophobic Aβ42 isoform has a higher tendency to generate neurotoxic oligomeric species.9,10”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although Aβ40 is present in larger amounts in the brain, Aβ42 was found to be more neurotoxic and have a higher tendency to aggregate.4,5”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Although it was shown in previous studies9,10,21 that the Aβ42 peptide is more prone to form neurotoxic soluble Aβ oligomers than the Aβ40 peptide”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…potently disrupt synaptic plasticity (Klyubin et al, 2008; Shankar et al, 2008), an Ab species of 56 kDa has been found neurotoxic in Tg2576 mice (Lesne et al, 2006), lipid-induced oligomers from mature fibrils (Martins et al, 2008), ADDLs (Lambert et al, 1998; Gong et al, 2003; Lacor et al,…”
BackgroundRetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Flagged first, then by citations
1 of the 61 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 538
Republished: The role of amyloid β in the pathogenesis of Alzheimer’s disease
Gilbert, B. J. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-201515rep · Cited by 20
Acharya, S., Srivastava, K. R., Nagarajan, S., & Lapidus, L. J. (2016) · ChemPhysChem · doi:10.1002/cphc.201600706 · Cited by 20
Specific Triazine Herbicides Induce Amyloid-β 42 Production
Portelius, E., Durieu, É., Bodin, M., Cam, M., Pannee, J., Leuxe, C., Mabondzo, A. M., Oumata, N., Galons, H., Lee, J. Y., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160310 · Cited by 21
Negi, N., & Das, B. K. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2019.1711073 · Cited by 20
Ngô, S. T., Nguyen, P. H., & Derreumaux, P. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b11881 · Cited by 20
From defense to disease: IFITM3 in immunity and Alzheimer's disease
Kehs, Z., Cross, A. C., & Li, Y. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00482 · Cited by 21
Dehydroevodiamine·HCl enhances cognitive function in memory-impaired rat models
Shin, K. Y., Kim, K. Y., & Suh, Y. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.1.55 · Cited by 19
Wahlberg, E., Rahman, M. M., Lindberg, H., Gunneriusson, E., Schmuck, B., Lendel, C., Sandgren, M. O. J., Löfblom, J., Ståhl, S., & Härd, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-06377-8 · Cited by 19
Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy
Nieznańska, H., Bandyszewska, M., Surewicz, K. A., Zajkowski, T., Surewicz, W. K., & Nieznański, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.023 · Cited by 19
The cAMP/PKA Pathway Inhibits Beta-amyloid Peptide Release from Human Platelets
Sepulveda, C. A., Hernández, B., Burgos, C. F., Eduardo Fuentes, Q., Palomo, I. F., & Alarcón, M. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.025 · Cited by 20
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 18
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 18
Tian, Y., Shang, Q., Liang, R., & Viles, J. H. (2024) · JACS Au · doi:10.1021/jacsau.3c00687 · Cited by 18
Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms
Im, D., & Choi, T. S. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0044 · Cited by 19
Jeong, D., Kim, J., Chae, M.-S., Lee, W., Yang, S.-H., Kim, Y., Kim, S., Lee, J., Lee, J., Choi, J., et al. (2018) · Italian National Conference on Sensors · doi:10.3390/s18061738 · Cited by 19
Tamano, H., Takiguchi, M., Tanaka, Y., Murakami, T., Adlard, P. A., Bush, A. I., & Takeda, A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01853-w · Cited by 18
Use of standard U-bottom and V-bottom well plates to generate neuroepithelial embryoid bodies
Buentello, D. C., Koch, L. S., Santiago, G. T., Álvarez, M. M., & Broersen, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262062 · Cited by 18
Self-citationKretner, B., Fukumori, A., Kuhn, P., Pérez‐Revuelta, B. I., Lichtenthaler, S. F., Haass, C., & Steiner, H. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12124 · Cited by 18
Svedružić, Ž. M., Popović, K., Smoljan, I., & Jengić, V. Š. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032293 · Cited by 18
Fröhlich, C., Paarmann, K., Steffen, J., Stenzel, J., Krohn, M., Heinze, H., & Pahnke, J. (2013) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.3.2013.1.3 · Cited by 17
Terrill, S. E., Colvin, B. A., Davenport, R. E., & Nichols, M. R. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.03.017 · Cited by 18
Yuksel, M., Biberoğlu, K., Önder, S., AKBULUT, K. G., & Tacal, Ö. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.004 · Cited by 17
Wu, Y., Yang, J., Geng, Y., Jiao, X., Lü, Z., Zhang, T., Zhao, R., Guo, J., Wang, W., Wang, J., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302851 · Cited by 16
Naskar, R., Ghosh, A., Bhattacharya, R., & Chakraborty, S. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105859 · Cited by 16
Nanobodies as Structural Probes of Protein Misfolding and Fibril Formation
Genst, E. D., & Dobson, C. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_34 · Cited by 16
The Role of Neutrophil Proteins on the Amyloid Beta-RAGE Axis
Stock, A. J., Kasus‐Jacobi, A., Wren, J. D., Sjoelund, V. H., Prestwich, G. D., & Pereira, H. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163330 · Cited by 16
Li, J.-M., Xue, Z.-Q., Deng, S.-H., Luo, X.-G., Patrylo, P. R., Rose, G. W., Cai, H., Cai, Y., & Yan, X.-X. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9355-2 · Cited by 16
Cheng, F., Ruscher, K., Fransson, L., & Mani, K. (2013) · Glycobiology · doi:10.1093/glycob/cwt079 · Cited by 17
Synthetic toxic Aβ 1–42 oligomers can assemble in different morphologies
Bobo, C., Chaignepain, S., Henry, S., Vignaud, H., Améadan, A., Marchal, C., Prado, É., Doutch, J., Schmitter, J., Nardin, C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.03.001 · Cited by 16
Sekioka, R., Honda, S., Akashiba, H., Yarimizu, J., Mitani, Y., & Yamasaki, S. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115455 · Cited by 15
Liang, R., Tian, Y., & Viles, J. H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102071 · Cited by 15
Cheng, Y.-H., Lai, S., Chen, P.-Y., Chang, J., & Chang, N. W. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9485-9 · Cited by 15
Discovery of novel scaffolds for γ-secretase modulators without an arylimidazole moiety
Sekioka, R., Honjo, E., Honda, S., Fuji, H., Akashiba, H., Mitani, Y., & Yamasaki, S. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.049 · Cited by 15
The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
Murray, C. E., Gami‐Patel, P., Gkanatsiou, E., Brinkmalm, G., Portelius, E., Wirths, O., Heywood, W., Blennow, K., Ghiso, J. A., Holton, J. L., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0563-8 · Cited by 15
Kim, H. Y., Lee, D., Ryu, K., & Choi, I. (2017) · Chemical Communications · doi:10.1039/c7cc00358g · Cited by 15
Tehrani, M. J., Matsuda, I., Yamagata, A., Kodama, Y., Matsunaga, T., Sato, M., Toyooka, K., McElheny, D., Kobayashi, N., Shirouzu, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51294-w · Cited by 14
Deleanu, M., Deschaume, O., Cipelletti, L., Hernandez, J., Bartic, C., Cottet, H., & Chamieh, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00784 · Cited by 14
Self-citationAyabe, T., Takahashi, C., Ohya, R., & Ano, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202101366rr · Cited by 15
In-Depth Characterization of Endo-Lysosomal Aβ in Intact Neurons
McKendell, A. K., Houser, M. C., Mitchell, S. P. C., Wolfe, M. S., Berezovska, O., & Maesako, M. (2022) · Biosensors · doi:10.3390/bios12080663 · Cited by 15
Sticker-and-spacer model for amyloid beta condensation and fibrillation
Connor, J. P., Quinn, S. D., & Schaefer, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.962526 · Cited by 14
Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins
Casaletto, K. B., Zetterberg, H., Blennow, K., Brinkmalm, A., Honer, W. G., Schneider, J. A., Bennett, D. A., Djukic, N. A., You, M. Y., Weiner‐Light, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012145 · Cited by 14
Colin, J., Allouche, A., Chauveau, F., Corbier, C., Gregory, L., Lanhers, M., Claudepierre, T., Yen, F. T., Oster, T., & Malaplate, C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151110 · Cited by 14
Payne, T., Taylor, J., Casey, C., Kunkel, D., Parker, M., Blennow, K., Zetterberg, H., Pearce, R. A., Lennertz, R. C., & Sanders, R. D. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.01.020 · Cited by 14
Overexpression of MTERF4 promotes the amyloidogenic processing of APP by inhibiting ADAM10
Wang, X., Liu, Q., Chen, G., Li, M., & Ding, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.135 · Cited by 13
de Matos, A. M., Man, T., Idrissi, I. G. E., Souza, C. D. S., Mead, E., Dunbar, C., Wolak, J., Oliveira, M. C., Evans, D. A. P., Grayson, J. D., et al. (2019) · Pure and Applied Chemistry · doi:10.1515/pac-2019-0114 · Cited by 13
Welty, S., Thathiah, A., & Levine, A. S. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220030 · Cited by 13
Biological Effects and Mechanisms of Taurine in Various Therapeutics
Sharma, S., Sahoo, B. M., & Banik, B. K. (2023) · Current Drug Discovery Technologies · doi:10.2174/1570163820666230525101353 · Cited by 14
Hector, A., Provost, C., Delignat‐Lavaud, B., Bouamira, K., Menaouar, C.-A., Mongrain, V., & Brouillette, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01316-4 · Cited by 14
Intrinsically disordered protein domains in flavivirus infection
Martins, I. C., & Santos, N. C. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108298 · Cited by 13
Self-citationAssessing Reproducibility in Amyloid β Research: Impact of Aβ Sources on Experimental Outcomes
Foley, A. R., & Raskatov, J. A. (2020) · ChemBioChem · doi:10.1002/cbic.202000125 · Cited by 13
Wang, Z., Gao, C., Zhang, L., & Sui, R. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123169 · Cited by 12
RetractedNam, E., Lin, Y., Park, J., Do, H., Han, J., Jeong, B., Park, S., Lee, D. Y., Kim, M., Han, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202307182 · Cited by 12
In Vitro Models of Brain Disorders
le Feber, J. (2019) · Advances in neurobiology · doi:10.1007/978-3-030-11135-9_2 · Cited by 13
Babylon, L., Schmitt, F., Franke, Y., Hubert, T., & Eckert, G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158670 · Cited by 12
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities
Asante, J., & Barger, S. W. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2495632 · Cited by 11
Cao, J., Zhang, C., Lo, C. Z., Guo, Q., Ding, J., Luo, X., Zhang, Z., Chen, F., Cheng, T., Chen, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14444 · Cited by 11
Understanding familial Alzheimer's disease: The fit‐stay‐trim mechanism of γ‐secretase
Mehra, R., & Kepp, K. P. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1556 · Cited by 11
Motta, C., Donna, M. G. D., Bonomi, C. G., Assogna, M., Chiaravalloti, A., Mercuri, N. B., Koch, G., & Martorana, A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01291-w · Cited by 11
Genomic stress and impaired DNA repair in Alzheimer disease
Neven, J., Issayama, L. K., Dewachter, I., & Wilson, D. M. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103678 · Cited by 12
Suganthy, N., Malar, D. S., & Devi, K. P. (2016) · Neurological Research · doi:10.1080/01616412.2016.1244374 · Cited by 11
Dutta, M., & Mattaparthi, V. S. K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1296783 · Cited by 11
Chen, L., Tseng, H.-J., Liu, C., Huang, Y., Yen, C.-C., Weng, J., Lu, Y., Hou, W., Lin, T. E., Pan, I.-H., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00708 · Cited by 11
Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer’s disease
Sheu, J., Yang, L., Sanotra, M. R., Wang, S., Lu, H., Kam, R. S. Y., Hsu, I.-U. Y., Kao, S., Lee, C., Shieh, J. C.-C., et al. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.11.011 · Cited by 11
Janssen, L., Keppens, C., Deyn, P. P. D., & Dam, D. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.027 · Cited by 11
Alzheimer’s Aβ catalyzes Tau phase separation and aggregation via early nanocluster solubilization
Sun, X., Tang, Y., Wang, X., Curia, G. P., Sternke‐Hoffmann, R., Mörman, C., Gerez, J., Riek, R., Wei, G., & Luo, J. (2026) · Nature Communications · doi:10.1038/s41467-026-70083-1 · Cited by 11
Ghalayini, J., & Boulianne, G. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1166973 · Cited by 10
Ziegler, T., Tsiountsioura, M., Meixner-Götz, L., Cvirn, G., & Lamprecht, M. (2023) · Nutrients · doi:10.3390/nu15173770 · Cited by 10
SAR investigations on a novel class of gamma-secretase modulators based on a unique scaffold
Austin, W., Hubbs, J. L., Fuller, N. O., Creaser, S. P., McKee, T. D., Loureiro, R. M. B., Findeis, M. A., Tate, B. A., Ives, J. L., & Bronk, B. S. (2013) · MedChemComm · doi:10.1039/c3md20357c · Cited by 10
γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease
Johnson, D. S., & Pettersson, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_19 · Cited by 10
Bergkvist, L., Sandin, L., Kågedal, K., & Brorsson, A. (2016) · Biology Open · doi:10.1242/bio.017194 · Cited by 10
Balgoon, M. J., Ahmed, G. A.-R., Qusti, S. Y., & Ali, S. S. (2018) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2018.11.001 · Cited by 10
Li, H., Luo, X.-B., Xu, Y., & Hou, X. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190207 · Cited by 10
Sahoo, S., Pal, T., Mondal, S., Ghanta, K. P., & Bandyopadhyay, S. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c05490 · Cited by 9
Tagami, S., Okochi, M., Yanagida, K., Kodama, T. S., Arai, T., Kuwano, R., Ikeuchi, T., & Takeda, M. (2013) · Neurodegenerative Diseases · doi:10.1159/000355258 · Cited by 9
Iron treatment inhibits Aβ42 deposition in vivo and reduces Aβ42/Aβ40 ratio
Shen, X., Liu, J., Fujita, Y., Liu, S., Maeda, T., Kikuchi, K., Obara, T., Takebe, A., Sayama, R., Takahashi, T., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.119 · Cited by 9
Grayson, J. D., Baumgartner, M. P., Souza, C. D. S., Dawes, S. J., Idrissi, I. G. E., Louth, J. C., Stimpson, S., Mead, E., Dunbar, C., Wolak, J., et al. (2021) · Chemical Science · doi:10.1039/d0sc04769d · Cited by 10
Mutual structural effects of unmodified and pyroglutamylated amyloid β peptides during aggregation
Abedin, F., & Tatulian, S. A. (2021) · Journal of Peptide Science · doi:10.1002/psc.3312 · Cited by 9
The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease
Gomes, B., Loureiro, J. A., Coelho, M. A. N., & Pereira, M. D. C. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150130120358 · Cited by 9
Boyle, J. P., Hettiarachchi, N. T., Wilkinson, J. A., Pearson, H. A., Scragg, J. L., Lendon, C. L., Al‐Owais, M. M., Kim, C. B., Myers, D., Warburton, P., et al. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.061 · Cited by 9
Kusko, M., Craciunoiu, F., Amuzescu, B. P., Halitzchi, F., Şelescu, T., Radoi, A., Popescu, M., Simion, M., Brăgaru, A., & Ignat, T. (2012) · Sensors · doi:10.3390/s121216571 · Cited by 9
Singhal, S., Khanna, P., Misra, N., & Khanna, L. (2021) · ChemistrySelect · doi:10.1002/slct.202004635 · Cited by 9
The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1
Liu, L., Schultz, S. A., Saba, A., Yang, H., Li, A., Selkoe, D. J., & Chhatwal, J. P. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14339 · Cited by 9
Yi, Y., Kim, K., Kim, H., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06070a · Cited by 8
A Hexameric Peptide Barrel as Building Block of Amyloid‐β Protofibrils
Lendel, C., Bjerring, M., Dubnovitsky, A. P., Kelly, R. T., Filippov, A. V., Antzutkin, O. N., Nielsen, N. C., & Härd, T. (2014) · Angewandte Chemie · doi:10.1002/ange.201406357 · Cited by 8
Amyloids on Membrane Interfaces: Implications for Neurodegeneration
Mahakud, A. K., Shaikh, J., Iqbal, V. V. R., Gupta, A., Tiwari, A., & Saleem, M. (2022) · The Journal of Membrane Biology · doi:10.1007/s00232-022-00245-x · Cited by 8
Development of an accelerated cellular model for early changes in Alzheimer’s disease
Xue, H., Gate, S., Gentry, E., Losert, W., & Cao, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-45826-5 · Cited by 8
Lü, W., Shue, F., Kurti, A., Jeevaratnam, S., Macyczko, J. R., Roy, B., Izhar, T., Wang, N., Bu, G., Kanekiyo, T., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.10.005 · Cited by 9
Conceição, M., Filippo, L. D. D., Duarte, J. L., Beserra, F. P., Gremião, M. P. D., & Chorilli, M. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100894 · Cited by 8
Sun, W., Netzer, W. J., Sinha, A., Gindinova, K., Chang, E., & Sinha, S. C. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02007 · Cited by 8
Kumari, A., Shrivastava, N., Mishra, M., Somvanshi, P., & Grover, A. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103612 · Cited by 8
Differential Effects of Human P301L Tau Expression in Young versus Aged Mice
Hunsberger, H. C., Setti, S. E., Rudy, C. C., Weitzner, D. S., Pfitzer, J. C., McDonald, K. L., Hong, H., Bhattacharya, S., Suppiramaniam, V. D., & Reed, M. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111637 · Cited by 10
Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells
Önder, S., Biberoğlu, K., Yuksel, M., & Tacal, Ö. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110126 · Cited by 8
Ranade, D. S., Shravage, B. V., Kumbhar, A. A., Sonavane, U., Jani, V., Joshi, R., & Kulkarni, P. P. (2017) · ChemistrySelect · doi:10.1002/slct.201700588 · Cited by 8
Sekioka, R., Honda, S., Honjo, E., Suzuki, T., Akashiba, H., Mitani, Y., & Yamasaki, S. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115132 · Cited by 8
Cui, X., Zhang, F., Zhang, H., Huang, X., Wang, K., Huang, T., Yang, X., & Zou, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.583628 · Cited by 8
Membrane Charge Drives the Aggregation of TDP-43 Pathological Fragments
Corucci, G., Vadukul, D. M., Paracini, N., Laux, V., Batchu, K. C., Aprile, F. A., & Pastore, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00594 · Cited by 7
Viles, J. H. (2023) · Angewandte Chemie · doi:10.1002/ange.202215785 · Cited by 7
Sun, Y., Shi, Y., Li, C., & Shi, H. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c02343 · Cited by 7
Haessler, A., Gier, S., Jung, N., & Windbergs, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1516093 · Cited by 8
Metadata
- Authors
- Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, F., Schymkowitz, J., & De Strooper, B.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Vrije Universiteit Brussel (BE)
- Rega Institute for Medical Research (BE)
- University of Twente (NL)
- IMEC (BE)
- Corresponding author
- Schymkowitz, Joost
- ORCID
- Venue
- The EMBO Journal
- Published
- 2010-09-03
- Volume
- 29
- Issue
- 19
- Pages
- 3408-3420
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC2957213
- OpenAlex
- W1966694507
- Cited by
- 532
- References
- 61
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 36 · 2023: 39 · 2022: 27 · 2021: 39 · 2020: 32 · 2019: 33 · 2018: 31 · 2017: 35 · 2016: 48 · 2015: 31 · 2014: 30 · 2013: 42 · 2012: 43
- FWCI
- 24.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- University of Twente Research Information (publishedVersion, other-oa)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- University of Twente Research Information (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Commission (200611)
- Fonds Wetenschappelijk Onderzoek (P6/43)
- Vlaamse regering
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, Aβ42/Aβ40 ratio, neurotoxicity, oligomeric intermediates, fibril morphology, synaptic dysfunction, neuronal cell death, anti-amyloid therapy, peptide mixtures
- MeSH terms
- Alzheimer Disease, Analysis of Variance, Animals, Biophysics, Fluorescent Dyes, Humans, Kinetics, Microelectrodes, Neurons, Peptide Fragments, Protein Binding, Thiazoles, Amyloid beta-Peptides, Spectroscopy, Fourier Transform Infrared, Patch-Clamp Techniques, Microscopy, Electron, Transmission, Mice, Benzothiazoles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
